Case Study: MabVax Therapeutics strengthens competitive intelligence with Clarivate Cortellis

‘Insufficient’ data spurs an upgrade in competitive intelligence

MabVax Therapeutics, an early-stage San Diego biopharma company developing the MVT-5873 monoclonal antibody and a cancer vaccine, needed stronger competitive intelligence to support partnering discussions. After its new vice president and chief business officer, Paul Resnick, found the existing CI tool to be “insufficient,” the company needed a better way to identify competitors, compare assets, and prepare for tough questions from potential partners. Clarivate’s Cortellis Competitive Intelligence was the product used.

MabVax upgraded to Clarivate’s more robust Cortellis platform, with training for its executive team and access to targeted competitive and deals intelligence. Using Clarivate, Resnick could quickly benchmark competing programs, find relevant deal comparables, and build stronger arguments for term sheet negotiations. The result was better-informed partnering discussions and a clearer competitive picture, helping MabVax avoid gaps that could have become a deal killer.

MabVax Therapeutics

Paul Resnick

Vice President and Chief Business Officer